Quick Answer
MOLECULAR PARTNERS AG reported Research And Development Expense of $40.19 million for the year ending 2025.
- MOLECULAR PARTNERS AG showed a decrease of -17.3% in Research And Development Expense from 2024 to 2025.
- This data is from MOLECULAR PARTNERS AG's annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), MOLECULAR PARTNERS AG's Research And Development Expense has declined by 7.6%.
- Historical annual values: Fiscal year 2025: $40.19 million | Fiscal year 2024: $48.60 million | Fiscal year 2023: $48.78 million | Fiscal year 2022: $50.75 million | Fiscal year 2021: $55.72 million | Fiscal year 2020: $56.08 million | Fiscal year 2019: $43.50 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: